Phase 1, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies

Johnson M, El-Khoueiry A, Hafez N, et. al. Clin Cancer Res. June 7, 2021; doi: 10.1158/1078-0432.CCR-21-0194.